Pages that link to "Q78853135"
Jump to navigation
Jump to search
The following pages link to Reducing cardiovascular risk in type 2 diabetes (Q78853135):
Displaying 13 items.
- Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress (Q24805294) (← links)
- Reducing CVD risk in type 2 DM (Q28165324) (← links)
- Cluster-Randomized Trial of a Mobile Phone Personalized Behavioral Intervention for Blood Glucose Control (Q35179973) (← links)
- Effectiveness and cost-effectiveness of knowledge transfer and behavior modification interventions in type 2 diabetes mellitus patients--the INDICA study: a cluster randomized controlled trial (Q35425269) (← links)
- Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus (Q35989422) (← links)
- Marked hyperglycemia attenuates anesthetic preconditioning in human-induced pluripotent stem cell-derived cardiomyocytes. (Q36283727) (← links)
- Post-transplant diabetes mellitus: risk reduction strategies in the elderly (Q36635470) (← links)
- Risk factor management to prevent first stroke (Q37153566) (← links)
- Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies (Q37412941) (← links)
- Perception of health and understanding of cardiovascular risk among patients with recently diagnosed diabetes and/or metabolic syndrome (Q45120130) (← links)
- Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: a 30-year follow-up study of 740 incident patients with Type 2 diabetes (Q45897087) (← links)
- Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol (Q51391705) (← links)
- Multifactorial Intervention and Cardiovascular Disease in Type 2 Diabetes (Q73366976) (← links)